SCYNEXISSTU:135 43 Days Payable is 0.00 as of Mar. 2026. GuruFocus rates STU:135 with a GF Score™ of 43/100 and a GF Value™ of €19.77 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 923 Drug Manufacturers companies, SCYNEXIS ranks worse than 108342.25% on this metric.
The historical rank and industry rank for SCYNEXIS's Days Payable or its related term are showing as below:
During the past 13 years, SCYNEXIS's highest Days Payable was 7304.09. The lowest was 152.85. And the median was 4005.99.
STU:135's Days Payable is not ranked *
in the Drug Manufacturers industry.
Industry Median: 90.98 * Ranked among companies with meaningful Days Payable only.
SCYNEXIS's Days Payable
stayed the same
from Mar. 2025 (0.00) to Mar. 2026 (0.00).
stayed the same
SCYNEXIS Days Payable Related Terms
SCYNEXIS Days Payable Historical Data
* Premium members only.
The historical data trend for SCYNEXIS's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:135 vs ETST, BGM, INCR: Days Payable Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, SCYNEXIS's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SCYNEXIS Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, SCYNEXIS's Days Payable distribution charts can be found below:
* The bar in red indicates where SCYNEXIS's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
SCYNEXIS's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SCYNEXIS (STU:135) has a Days Payable of 0.00 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on SCYNEXIS and its competitors. Over the past decade, SCYNEXIS's Days Payable has ranged from 152.85 to 7,304.09. According to the industry distribution chart, SCYNEXIS ranks #999999 out of 923 companies in the Drug Manufacturers industry.
Is SCYNEXIS's Days Payable too high?
SCYNEXIS's current Days Payable is 0.00. Over the past 10 years, this metric has ranged from a low of 152.85 to a high of 7,304.09. Based on the distribution chart, SCYNEXIS ranks #999999 out of 923 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, SCYNEXIS has a GF Score™ of 43/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does SCYNEXIS's Days Payable compare to ETST and BGM?
According to the Drug Manufacturers industry distribution chart, SCYNEXIS ranks #999999 out of 923 companies for Days Payable. This places SCYNEXIS in the lower half of its industry. The industry median Days Payable is 90.98. Historically, SCYNEXIS's own Days Payable has ranged from 152.85 to 7,304.09 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.98, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on SCYNEXIS and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SCYNEXIS's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SCYNEXIS stock overvalued right now?
Based on GuruFocus' analysis, SCYNEXIS (STU:135) is currently considered Possible Value Trap. The stock's GF Value™ is €19.77, compared to a current price of €4.84 — trading 75.5% below its estimated fair value. The current Days Payable is 0.00. SCYNEXIS's overall GF Score™ is 43/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For SCYNEXIS (STU:135), the current Days Payable is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SCYNEXIS (STU:135) Overvalued in 2026?
Based on GuruFocus' analysis, SCYNEXIS stock appears to be undervalued.
The current stock price of €4.84 is trading 75.5% below its estimated GF Value™ of €19.77.
GuruFocus considers SCYNEXIS to be Possible Value Trap.
Key valuation signals for STU:135:
Days Payable: 0.00
GF Value™: €19.77 vs. price of €4.84 (75.5% below fair value)
No single metric tells the full story. See the STU:135 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
43GF Score
Get the complete analysis for STU:135
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:135 has been successfully added to your 
